Cardil (enalapril maleate): Uses, Dosage & Side Effects

What it's for (Indications)

Enalapril maleate is an angiotensin-converting enzyme (ACE) inhibitor indicated for the treatment of various cardiovascular conditions.
Its primary indications include the management of hypertension, either as monotherapy or in combination with other antihypertensive agents, to effectively lower blood pressure and reduce the risk of associated cardiovascular events such as stroke, myocardial infarction, and chronic kidney disease progression.
Furthermore, enalapril is specifically indicated for the treatment of symptomatic congestive heart failure, where it has demonstrated significant benefits in improving patient survival, reducing hospitalization rates, and ameliorating debilitating symptoms like dyspnea and fatigue by decreasing cardiac workload and improving left ventricular function.
It is also approved for the prevention of symptomatic heart failure in patients with asymptomatic left ventricular dysfunction, acting to delay the progression of the disease and prevent major cardiovascular events, thereby improving long-term patient outcomes.
The clinical efficacy and safety of enalapril in these indications have been rigorously established through extensive clinical trials.

Dosage Information

Type	Guideline
Standard	The dosage of enalapril maleate must be carefully individualized for each patient based on their clinical response, renal function, and concomitant medications to optimize therapeutic benefit while minimizing adverse effects. For the treatment of hypertension, the usual initial oral dose for adults is 5 mg once daily, which may be adjusted based on the patient's blood pressure response, typically ranging from 10 mg to 40 mg per day, administered as a single dose or in two divided doses. For symptomatic congestive heart failure, the initial dose is generally lower, starting at 2.5 mg once daily, and meticulously titrated upward over several weeks as tolerated, usually to a target maintenance dose of 10 mg to 20 mg daily, administered in single or divided doses. In patients with significant renal impairment or those concurrently receiving diuretic therapy, a substantially lower starting dose is often recommended to mitigate the risk of profound hypotension or renal dysfunction. Regular monitoring of blood pressure, renal function, and serum electrolytes (particularly potassium) is essential during dosage initiation and titration, especially in vulnerable populations such as the elderly or those with pre-existing kidney disease.

Type

Guideline

Standard

The dosage of enalapril maleate must be carefully individualized for each patient based on their clinical response, renal function, and concomitant medications to optimize therapeutic benefit while minimizing adverse effects. For the treatment of hypertension, the usual initial oral dose for adults is 5 mg once daily, which may be adjusted based on the patient's blood pressure response, typically ranging from 10 mg to 40 mg per day, administered as a single dose or in two divided doses. For symptomatic congestive heart failure, the initial dose is generally lower, starting at 2.5 mg once daily, and meticulously titrated upward over several weeks as tolerated, usually to a target maintenance dose of 10 mg to 20 mg daily, administered in single or divided doses. In patients with significant renal impairment or those concurrently receiving diuretic therapy, a substantially lower starting dose is often recommended to mitigate the risk of profound hypotension or renal dysfunction. Regular monitoring of blood pressure, renal function, and serum electrolytes (particularly potassium) is essential during dosage initiation and titration, especially in vulnerable populations such as the elderly or those with pre-existing kidney disease.

Safety & Warnings

Common Side Effects

Enalapril maleate, while generally well-tolerated, can cause a range of side effects, varying in severity and frequency.
Common side effects include a persistent, non-productive dry cough, which is a class effect of ACE inhibitors and often leads to discontinuation; dizziness and lightheadedness, particularly upon standing (orthostatic hypotension), fatigue, and headache, often attributable to the hypotensive effects of the medication.
More serious and potentially life-threatening adverse events include symptomatic hypotension, especially in volume-depleted patients or those with severe congestive heart failure, which can lead to syncope.
Renal dysfunction or acute renal failure can develop, particularly in patients with pre-existing renal disease, severe congestive heart failure, or bilateral renal artery stenosis.
Hyperkalemia (elevated potassium levels) is another significant concern, especially in patients with renal impairment, diabetes mellitus, or those concurrently using potassium-sparing diuretics or potassium supplements.
Angioedema, characterized by rapid swelling of the face, lips, tongue, glottis, and/or larynx, is a rare but potentially fatal side effect requiring immediate medical intervention.
Other less common but serious effects may include hepatic failure, pancreatitis, and various hematologic abnormalities.
Patients should be advised to report any new or worsening symptoms promptly to their healthcare provider.

Serious Warnings

Black Box Warning: ### FETAL TOXICITY * **When pregnancy is detected, discontinue enalapril maleate as soon as possible.** * **Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.** Exposure to enalapril during the second and third trimesters of pregnancy is known to cause fetotoxicity in humans. This includes **oligohydramnios**, which can result in fetal lung hypoplasia, skeletal deformities (e.g., craniofacial deformities, limb contractures), and delayed ossification of the skull. Neonatal adverse effects from *in utero* exposure to ACE inhibitors include anuria, hypotension, renal failure, and death. Infants with a history of *in utero* exposure to ACE inhibitors should be closely observed for hypotension, oliguria, and hyperkalemia. These adverse outcomes are believed to be due to the drug's direct effects on the fetal renin-angiotensin system, which plays a critical role in fetal kidney development and blood pressure regulation. Therefore, women of childbearing potential should be informed of the potential risks to the fetus and counselled on the use of effective contraception during therapy with enalapril. If pregnancy occurs, the medication should be discontinued immediately, and alternative antihypertensive therapies considered. Healthcare providers should review patient's pregnancy status regularly.
Several critical warnings are associated with the use of enalapril maleate.
**Hypotension**, especially symptomatic hypotension, can occur, particularly in volume-depleted patients (e.
g.
, those on high-dose diuretics, undergoing dialysis, or with recent vomiting/diarrhea) or those with severe congestive heart failure; initial doses should be carefully adjusted, and patients monitored closely, especially during the first few weeks of therapy.
**Renal impairment** or acute renal failure can develop, particularly in patients with pre-existing renal disease, severe congestive heart failure, or bilateral renal artery stenosis; renal function should be monitored regularly before and during therapy.
**Hyperkalemia** (elevated serum potassium) may occur, particularly in patients with renal impairment, diabetes mellitus, or those concurrently taking potassium-sparing diuretics, potassium supplements, or other drugs that increase potassium (e.
g.
, trimethoprim, NSAIDs).
**Angioedema** of the face, extremities, lips, tongue, glottis, and/or larynx has been reported with ACE inhibitors, including enalapril, and can be life-threatening due to airway obstruction; patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk.
**Anaphylactoid reactions** have been reported in patients undergoing desensitization treatment with Hymenoptera venom or during hemodialysis with high-flux membranes.
The risk-benefit profile should be carefully assessed prior to initiating therapy with enalapril.

How it Works (Mechanism of Action)

Enalapril maleate functions as a prodrug that undergoes hydrolysis in the liver to its active metabolite, enalaprilat. Enalaprilat is a potent, long-acting angiotensin-converting enzyme (ACE) inhibitor. ACE is a peptidyl dipeptidase enzyme that plays a crucial role in the renin-angiotensin-aldosterone system (RAAS) by catalyzing the conversion of inactive angiotensin I to the potent vasoconstrictor substance angiotensin II. Angiotensin II is responsible for a multitude of physiological effects, including direct vasoconstriction, stimulation of aldosterone secretion from the adrenal cortex (leading to sodium and water retention), and promotion of sympathetic nervous system activity. By inhibiting ACE, enalaprilat effectively decreases plasma angiotensin II concentrations, which in turn leads to a reduction in systemic vasoconstrictor activity and decreased aldosterone secretion. This physiological cascade results in vasodilation, reduced systemic vascular resistance, and modest natriuresis and diuresis. The reduction in angiotensin II also attenuates its proliferative effects on vascular smooth muscle and cardiac myocytes, contributing to beneficial cardiovascular remodeling. Furthermore, ACE is also responsible for the degradation of bradykinin, a potent vasodilator; inhibition of ACE by enalaprilat leads to increased levels of bradykinin, which may contribute to its antihypertensive effect and the common side effect of cough. The overall therapeutic effect is a reduction in blood pressure, a decrease in cardiac preload and afterload, and improved hemodynamic parameters in conditions such as hypertension and heart failure.